Filing Flows › Nurix Therapeutics (NRIX) › Q4 FY24
Nurix Therapeutics (NRIX) Q4 FY24 earnings results (fourth quarter fiscal 2024)
10-K filed Jan 28, 2025
Nurix Therapeutics (NRIX) reported revenue of $13.3M for the fourth quarter fiscal 2024 (Q4 FY24), -12% from a year earlier and +6% from the quarter before. Operating margin was -486.7%, net loss $58.5M (440.7% of revenue).
Nurix Therapeutics, Q4 FY24: revenue $13.3M (-12% year over year), operating margin -486.7%, net loss $58.5M, operating cash flow −$48.8M. The chart follows the revenue to costs, profit and cash.
| Q4 FY24 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.3M | +6% | -12% |
| Operating profit | −$64.7M | — | — |
| Net earnings | −$58.5M | — | — |
| Operating cash flow | −$48.8M | — | — |
What changed
Revenue was $13.3M in Q4 FY24, down 12% year over year and up 6% from the previous quarter.
Operating costs exceeded revenue by $64.7M, an operating margin of -486.7%. Total costs grew 29% against a revenue fall of 12%. The fastest-growing cost line was Research & development (+35%). The quarter ended with a net loss of $58.5M, wider than the previous quarter's $49.0M loss.
Operating cash flow was −$48.8M. Non-cash charges added back $2.5M of depreciation and amortization and $8.5M of share-based compensation. Capital expenditures of $2.1M exceeded it, leaving free cash flow of −$50.9M.
Questions
What was Nurix Therapeutics' revenue in the fourth quarter fiscal 2024?
Nurix Therapeutics (NRIX) reported revenue of $13.3M for the fourth quarter fiscal 2024 (Q4 FY24), -12% from a year earlier and +6% from the quarter before.
Was Nurix Therapeutics profitable in the fourth quarter fiscal 2024?
Operating loss was $64.7M (-486.7% of revenue) and net loss $58.5M.
Source: Nurix Therapeutics 10-K on SEC EDGAR.